← Back to patent-cliff list
Desidustat
Tier C — Watch / tradeDesidustat
Zydus Cadila
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HIF-PHs
Brand：Oxemia
Indications (approved)：Anaemia
Regional status
US
-
EU
-
China
Approved
2026-03-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Desidustat?
Approved indications include: Anaemia.
When does the Desidustat patent expire?
No public expiry year is available for Desidustat yet; this page updates once verified.
How do I get a quote for Desidustat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27